• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Li Yan Michael

    11/7/22 5:20:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ADOC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Li Yan Michael

    (Last) (First) (Middle)
    C/O EDOC ACQUISITION CORP.
    7612 MAIN STREET FISHERS, SUITE 200

    (Street)
    VICTOR NY 14564

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/12/2022
    3. Issuer Name and Ticker or Trading Symbol
    Edoc Acquisition Corp. [ ADOC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    The reporting person has an indirect pecuniary interest in shares of Class B ordinary shares of the issuer through membership interests in American Physicians LLC, over which the reporting person does not have voting or dispositive control.
    No securities are beneficially owned.
    /s/ Yan Michael Li 11/07/2022
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ADOC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADOC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADOC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Yakira Capital Management, Inc. disposed of $2,662,742 worth of Class A Ordinary Shares (248,622 units at $10.71)

    4 - Edoc Acquisition Corp. (0001824884) (Issuer)

    2/23/23 5:01:04 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3: New insider Yakira Capital Management, Inc. claimed ownership of 275,000 units of Class A Ordinary Shares

    3 - Edoc Acquisition Corp. (0001824884) (Issuer)

    1/26/23 2:36:23 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Li Yan Michael

    3 - Edoc Acquisition Corp. (0001824884) (Issuer)

    11/7/22 5:20:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADOC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Edoc Acquisition Corp. Announces Postponement of Special Meeting of Shareholders on Proposed Business Combination

    Victor, NY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- EDOC Acquisition Corp. (NASDAQ:ADOC) ("EDOC") announced today that it has postponed its extraordinary general meeting of its shareholders (the "Meeting") to approve its proposed initial business combination, which was re-scheduled from February 26, 2024 to February 28, 2024, has been further postponed to 4:30p.m. Eastern Time, on Tuesday, March 5, 2024. At the Meeting, shareholders of EDOC will be asked to vote on proposals to approve, among other things, its proposed initial business combination with Australian Oilseeds Holdings Limited, a Cayman Islands exempted company ("Pubco"), pursuant to a Business Combination Agreement by and among EDOC

    2/27/24 5:32:10 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Edoc Acquisition Corp. Announces Postponement of Special Meeting of Stockholders on Proposed Business Combination

    Victor, NY, Feb. 23, 2024 (GLOBE NEWSWIRE) --  EDOC Acquisition Corp. (NASDAQ:ADOC) ("EDOC") announced today that it has postponed its extraordinary general meeting of its shareholders (the "Meeting") to approve its proposed initial business combination, which was scheduled for February 26, 2024, has been postponed to 10:00 a.m. Eastern Time, on Wednesday, February 28, 2024. At the Meeting, shareholders of EDOC will be asked to vote on proposals to approve, among other things, its proposed initial business combination with Australian Oilseeds Holdings Limited, a Cayman Islands exempted company ("Pubco"), pursuant to a Business Combination Agreement by and among EDOC, American Physicians LL

    2/23/24 5:45:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Australian Oilseeds and EDOC Acquisition Corp. Announce Effectiveness of Registration Statement and Date of Shareholder Meeting to Approve Proposed Business Combination

    ~ Shareholder Meeting of EDOC Acquisition Corp. to Approve Business CombinationScheduled for February 26, 2024 ~ ~ EDOC Shareholders of Record as of February 2, 2024, are Eligible to Vote at Meeting ~ ~ Upon Closing, Australian Oilseeds Investments Pty Ltd. is Expected to Trade on Nasdaq Under the Ticker "COOT" ~ Victor, NY and Cootamundra New South Wales, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Australian Oilseeds Holdings Limited, a Cayman Islands exempted company ("Australian Oilseeds" or "Pubco") and EDOC Acquisition Corp., a publicly-traded special purpose acquisition company ("EDOC") (NASDAQ:ADOC, ADOCW, ADOCR))), today announced that the Securities and Exchange Commission ("SEC")

    2/7/24 3:00:00 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADOC
    SEC Filings

    View All

    SEC Form 15-12G filed by Edoc Acquisition Corp.

    15-12G - Edoc Acquisition Corp. (0001824884) (Filer)

    4/1/24 6:02:12 AM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Edoc Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - Edoc Acquisition Corp. (0001824884) (Filer)

    3/28/24 5:16:10 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 25-NSE filed by Edoc Acquisition Corp.

    25-NSE - Edoc Acquisition Corp. (0001824884) (Subject)

    3/22/24 8:52:21 AM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADOC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    SC 13G/A - Edoc Acquisition Corp. (0001824884) (Subject)

    2/14/24 12:48:37 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    SC 13G/A - Edoc Acquisition Corp. (0001824884) (Subject)

    2/13/24 4:41:59 PM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Edoc Acquisition Corp. (Amendment)

    SC 13G/A - Edoc Acquisition Corp. (0001824884) (Subject)

    1/31/24 6:08:55 AM ET
    $ADOC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care